港澳台宝典免费资料-免费公开资料大全

  • Home
  • About Encode
    Our Company
    Our Business
    History
    Awards & Recognition
  • News
    Events
    Exhibitions
    Industry Information
  • Products
    Microbiology
    Immunology Qualitative Rapid Test
    Immunoflourescence Quantitative Rapid Test
    POCT
    Molecular Diagnostics
    Animal Tests
    Instruments and Consumables
  • Global Market
    Market Introduction
    Partnerships
  • Support
    Service Support
    Technical Support
    Downloads
  • Careers
    Employee Benefits
    Featured Jobs
  • Contact Us
    Contact Us
  • 中文 EN Alibaba
  • Home
  • About Encode
  • News
  • Products
  • Global Market
  • Support
  • Careers
  • Contact Us
  • 中文 EN
News Center
  • Events
  • Exhibitions
  • Industry Information
Siemens Launch Syphilis Assay for ADVIA Centaur
Date: 2011-08-29

Siemens Healthcare Diagnostics has announced the launch of its ADVIA Centaur® Syphilis Assay1 for the detection of antibodies against Treponema pallidum, a bacterium known to cause the sexually-transmitted disease syphilis. The assay has been CE-marked for use on Siemens’ ADVIA Centaur family of high-throughput, random-access immunoassay systems. 

Syphilis has been called the “great imposter” because its symptoms can mimic other infections in advanced stages2. When left untreated, syphilis can lead to serious neurological and cardiovascular complications, and cause stillbirth in pregnant women. Fortunately, detection of the presence of syphilis antibodies in patients may be used to support decisions for antibiotic therapy, detect persons at risk to spread the infection and identify those that are not aware of their infection, thus preventing late complications. Recently, a meta-analysis of 10 studies involving 41,049 women found that screening and treatment of the infection in pregnant women could reduce by more than half the number of stillbirths and perinatal deaths resulting from maternal transmission of syphilis3. 

“Testing for syphilis is a simple, yet effective tool for optimising health outcomes in at-risk patients,” said Dave Hickey, Chief Executive Officer, Chemistry, Immunoassay, Automation and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “Consolidating syphilis testing onto a single system addresses a critical challenge of laboratories today - to improve operational efficiency while delivering fast, accurate results that help guide clinicians in identifying and caring for patients affected by this disease.” 

Siemens offers an extensive portfolio of highly automated infectious disease assays (available on the ADVIA Centaur/XP/CP and IMMULITE® 2000 XPi immunoassay systems) compatible with laboratory automation. The addition of the syphilis assay to the ADVIA Centaur menu allows further consolidation of infectious disease testing onto a single platform, helping laboratories to improve their efficiency and deliver fast, accurate results.


0756-3983888
Headquarters address: No. 020, Honghui 2nd Road, Hongqi Industrial Zone, Jinwan District, Zhuhai City
Fax: 0756-3983809
Email: [email protected]
WeChat Official
Tuberculosis
About Encode
  • Our Company
  • Our Business
  • History
  • Awards & Recognition
News
  • Events
  • Exhibitions
  • Industry Information
Products
  • Microbiology
  • Immunology Qualitative Rapid Test
  • Immunoflourescence Quantitative Rapid Test
  • POCT
  • Molecular Diagnostics
  • Animal Tests
  • Instruments and Consumables
Global Market
  • Market Introduction
  • Partnerships
Support
  • Service
  • Technical Support
  • Download
Careers
  • Company benefits
  • Recruitment positions
Contact Us
  • Contact Us
  • No. 020, Honghui 2nd Road, Hongqi Industrial Zone, Jinwan District, Zhuhai City

  • 0756-3983809

  • [email protected]

Copyright(C)Zhuhai Encode Medical Engineering Co, Ltd Powered by: ll-wang.com

Copyright(C)Zhuhai Encode Medical Engineering Co, Ltd
Powered by: ll-wang.com